Change description : 2021-11-15 10:54:00: Updated to include second doses for 16 to 17 year olds and booster doses for 40 to 49 year olds; further clarification on booster timing flexibility; guidance on deferral after COVID-19 infection in under 18s and other minor edits for clarification. [Coronavirus (COVID-19)]
Ref: PHE gateway number 2020300PDF, 596KB696KB, 3940 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email publications@phe.gov.uk.
Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This chapter includes information on:
the coronavirus (COVID-19) vaccines
the dosage and schedule for the UK
recommendations for the use of the vaccine
Published 27 November 2020
Last updated 2915 OctoberNovember 2021
+ show all updates
Updated to include second doses for 16 to 17 year olds and booster doses for 40 to 49 year olds; further clarification on booster timing flexibility; guidance on deferral after COVID-19 infection in under 18s and other minor edits for clarification.
Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barré Syndrome after vaccination, clarifying flexibility around the booster timing and supply, additional evidence on booster dose effectiveness and on vaccination after monoclonal antibody products.
3 September 2021
Updated to include third dose primary vaccination for severely immunosuppressed patients and revised risk groups for children, PEG allergy advice, background information and regulatory information.
30 July 2021
Updated to include vaccinating at-risk children section, information and references on vaccines and evidence on vaccine effectiveness, cautions on rare conditions reported after vaccination, advice on schedules and emerging evidence on protection of immunosuppressed people.
1 July 2021
Updated with clarification around the schedule following the emergence of Delta variant, advice on cautions and contraindications, and co-administration advice. More evidence also added on vaccine effectiveness and mixed schedules.
7 May 2021
Updated to include additional information on the eligibility and safety of the AstraZeneca vaccine.
16 April 2021
Updated to incorporate recommendations for phase 2 of the programme and additional information on the safety of the AstraZeneca vaccine.
15 April 2021
Replaced with previous version.
15 April 2021
Updated to incorporate recommendations for phase 2 of the programme and additional information on the safety of the AstraZeneca vaccine.
12 February 2021
Updated to include information on the Moderna mRNa vaccine, further changes to the advice on managing allergic history and allergies after dose 1 and updated information and clarification of advice on pregnancy.
26 January 2021
Updated clarification around allergies.
21 January 2021
Updated to include changes to the advice on timing of vaccine in those being given immunosuppressive treatments and further detail on history of previous allergies.
31 December 2020
Added revised green book chapter 14a - additional information to reflect the MHRA approval of the Astra-Zeneca vaccine and to reflect updated advice on pregnancy and allergies for the Pfizer BioNTech vaccine, and the updated statement from the JCVI on scheduling.